IFC proposes West African pharma investment
The IFC has disclosed a proposed investment consisting of two loans totalling up to €50 million to the local subsidiaries of Tridem Pharma and Guilin Pharma.
Tridem Pharma, together with Guilin Pharma, are planning to expand their pharmaceutical production capacity and distribution capabilities in French-speaking Africa through the construction of a regional pharmaceutical distribution hub in Côte d’Ivoire and the greenfield construction of a local drug manufacturing facility in Côte d’Ivoire. The manufacturing facility in Côte d’Ivoire will primarily be used to manufacture anti-malaria drugs. The proposed IFC investment comprises of two A loans to the local subsidiaries of Tridem and Guilin Pharma for the implementation of the project.
Tridem is a French pharmaceutical distribution company with a substantial presence in Africa, which offers distribution solutions for pharmaceutical manufacturers, including regulatory affairs and licensing, promotion and distribution. Guilin Pharma is a Chinese pharmaceutical company and a leading producer of anti-malarial products, with its products being made available in over 80 countries globally.
Fosun Pharma is the sponsor for the project, and a 100% shareholder of Tridem and a 96% shareholder of Guilin Pharma.